Inhibrx, Inc. (NASDAQ: INBX) is a clinical-stage biotechnology company headquartered in San Diego, California, focused on developing novel therapeutic proteins using its proprietary single-domain antibody (sdAb) and multi-specific antibody platforms. The company is applying its technology to generate treatments for oncology, immunology, and neurodegenerative diseases[1].
Founded in 2010, Inhibrx has built a differentiated platform based on camelid-derived single-domain antibodies (nanobodies), which offer unique properties including small size, high affinity, stability, and the ability to engage multiple targets simultaneously[2].
| Program | Target/Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| INBRX-101 | Alpha-synuclein antibody | Parkinson's Disease | Preclinical | Research |
| INBRX-105 | Tau antibody | Alzheimer's Disease | Preclinical | Research |
| INBRX-109 | 4-1BB agonist | Oncology | Phase 1 | Active |
| INBRX-106 | PD-L1/4-1BB | Oncology | Phase 1 | Active |
| INBRX-102 | Undisclosed | CNS disorder | Discovery | Research |
INBRX-101 is a single-domain antibody targeting alpha-synuclein aggregates for Parkinson's disease and related disorders. The sdAb platform offers advantages in tissue penetration and clearance of aggregated proteins[3].
Mechanism of Action:
Advantages of sdAb Platform:
Development Status:
INBRX-105 is a tau-targeting single-domain antibody in preclinical development for Alzheimer's disease. The program leverages the same sdAb platform as INBRX-101[4].
Target:
Rationale:
INBRX-102 is an undisclosed CNS program in discovery research:
Inhibrx's proprietary platform enables development of next-generation biologics:
| Feature | Benefit |
|---|---|
| Small size | Better tissue penetration |
| High affinity | Potent target engagement |
| Stability | Extended half-life, manufacturing |
| Multi-specificity | Simultaneous targeting |
| Humanization | Reduced immunogenicity |
The company's SDIB (Single Domain Inverted Binder) platform enables multi-specificity:
INBRX-109 is a tetra-valent 4-1BB agonist in Phase 1 clinical trials for solid tumors:
INBRX-106 is a bi-specific antibody targeting PD-L1 and 4-1BB:
Key preclinical findings:
Key preclinical findings:
Inhibrx has established internal manufacturing capabilities:
| Partner | Focus Area | Status |
|---|---|---|
| Bristol Myers Squibb | SDIB technology | Collaboration |
| Academic collaborators | Research | Multiple |
| CRO partners | Clinical development | Active |